Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?Zacks Investment Research • 08/20/26
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive DyskinesiaPRNewsWire • 08/12/26
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple AgonistPRNewsWire • 08/07/26
NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives GrowthZacks Investment Research • 07/31/26
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 07/30/26
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 07/30/26
Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 07/29/26
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 07/23/26
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)Zacks Investment Research • 07/10/26
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial ResultsPRNewsWire • 07/09/26
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/08/26
Reasons Why Investors Should Consider Betting on Neurocrine StockZacks Investment Research • 07/06/26
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For SolenoSeeking Alpha • 07/02/26